Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 108,366 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 108,366 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $31.73, for a total transaction of $3,438,453.18. Following the transaction, the chief executive officer now owns 605,417 shares in the company, valued at approximately $19,209,881.41. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Andrew Cheng also recently made the following trade(s):

• On Friday, October 18th, Andrew Cheng sold 63,539 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.53, for a total transaction of $2,003,384.67.
• On Wednesday, October 16th, Andrew Cheng sold 24,992 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.14, for a total transaction of $778,250.88.
• On Tuesday, September 10th, Andrew Cheng sold 1,738 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total value of $45,500.84.

Akero Therapeutics Stock Down 1.6 %

Shares of NASDAQ AKRO traded down $0.50 during trading hours on Tuesday, hitting $31.55. The company had a trading volume of 7,638 shares, compared to its average volume of 869,998. The company has a current ratio of 24.89, a quick ratio of 24.89 and a debt-to-equity ratio of 0.04. Akero Therapeutics, Inc. has a 1-year low of $13.39 and a 1-year high of $37.00. The firm’s 50 day moving average is $28.42 and its 200-day moving average is $24.89.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.09. Analysts predict that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a research report on Tuesday, September 17th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.20.

Institutional Investors Weigh In On Akero Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC lifted its holdings in Akero Therapeutics by 42.2% during the 1st quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock valued at $154,589,000 after purchasing an additional 1,815,569 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Akero Therapeutics by 10.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company’s stock worth $102,569,000 after buying an additional 384,555 shares during the period. Vanguard Group Inc. increased its position in Akero Therapeutics by 19.0% during the 1st quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock worth $92,702,000 after buying an additional 584,875 shares during the period. Baker BROS. Advisors LP increased its position in Akero Therapeutics by 14.6% during the 1st quarter. Baker BROS. Advisors LP now owns 2,713,205 shares of the company’s stock worth $68,536,000 after buying an additional 344,827 shares during the period. Finally, Redmile Group LLC increased its position in Akero Therapeutics by 67.5% during the 1st quarter. Redmile Group LLC now owns 1,858,702 shares of the company’s stock worth $46,951,000 after buying an additional 749,226 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.